Checkpoint Therapeutics Receives Approval for PD-L1 Therapy
December 16, 2024
The approval of cosibelimab-ipdl provides an option for patients with cutaneous squamous cell carcinoma December 13, 2024 (Sacramento, California) The…
Recent Posts
Dec. 16, 2024
Checkpoint Therapeutics Receives Approval for PD-L1 Therapy
Dec. 03, 2024
Active Military Service Veterans are at Risk for Skin Cancers
Nov. 05, 2024
Nailing Down on the Ultraviolet Exposure Occurring During the Curing and Drying of a Manicure
Sep. 24, 2024
Social Awareness and Support Needed for Spouses of Patients Recently Diagnosed With Cancer
Sep. 16, 2024